In a filing, Viking Therapeutics Inc revealed its Director Rouan Sarah Kathryn acquired Company’s shares for reported $29943.0 on Mar 31 ’25. In the deal valued at $24.15 per share,1,240 shares were bought. As a result of this transaction, Rouan Sarah Kathryn now holds 1,240 shares worth roughly $30466.8.
Then, Lian Brian sold 194,490 shares, generating $8,313,601 in total proceeds. Upon selling the shares at $42.75, the President & CEO now owns 2,366,570 shares.
Before that, Mancini Marianna sold 54,215 shares. Viking Therapeutics Inc shares valued at $2,317,599 were divested by the Chief Operating Officer at a price of $42.75 per share. As a result of the transaction, Mancini Marianna now holds 374,134 shares, worth roughly $9.19 million.
Goldman initiated its Viking Therapeutics Inc [VKTX] rating to a Neutral in a research note published on April 08, 2025; the price target was $30. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid February with a ‘”a Sector outperform”‘ rating. Citigroup began covering VKTX with “Neutral” recommendation on February 07, 2025. Piper Sandler started covering the stock on December 02, 2024. It rated VKTX as “an Overweight”.
Price Performance Review of VKTX
On Monday, Viking Therapeutics Inc [NASDAQ:VKTX] saw its stock jump 10.58% to $24.57. Over the last five days, the stock has gained 15.46%. Viking Therapeutics Inc shares have fallen nearly -38.94% since the year began. Nevertheless, the stocks have fallen -65.33% over the past one year. While a 52-week high of $81.86 was reached on 01/06/25, a 52-week low of $18.92 was recorded on 04/09/25. SMA at 50 days reached $28.01, while 200 days put it at $48.17.
Levels Of Support And Resistance For VKTX Stock
The 24-hour chart illustrates a support level at 23.06, which if violated will result in even more drops to 21.56. On the upside, there is a resistance level at 26.58. A further resistance level may holdings at 28.60. The Relative Strength Index (RSI) on the 14-day chart is 47.05, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.90, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 39.05%. Stochastics %K at 38.77% indicates the stock is a holding.
How much short interest is there in Viking Therapeutics Inc?
A steep rise in short interest was recorded in Viking Therapeutics Inc stocks on 2025-03-31, growing by 1.71 million shares to a total of 25.62 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 23.91 million shares. There was a rise of 6.66%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 22, 2024 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $109 price target.
